Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(2.20)
# 2,755
Out of 5,106 analysts
119
Total ratings
40.19%
Success rate
-2.32%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYBN Cybin | Maintains: Buy | $70 → $45 | $7.85 | +473.25% | 9 | Nov 20, 2025 | |
| MNMD Mind Medicine (MindMed) | Maintains: Buy | $16 → $25 | $14.02 | +78.32% | 2 | Nov 7, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $25 → $24 | $8.53 | +181.36% | 7 | Nov 6, 2025 | |
| STOK Stoke Therapeutics | Maintains: Buy | $24 → $28 | $31.86 | -12.12% | 4 | Nov 5, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $160 → $164 | $147.28 | +11.35% | 17 | Oct 29, 2025 | |
| ATAI Atai Beckley | Maintains: Buy | $11 → $14 | $4.33 | +223.33% | 4 | Oct 22, 2025 | |
| ANVS Annovis Bio | Maintains: Buy | $17 | $3.58 | +374.86% | 4 | Sep 30, 2025 | |
| CLNN Clene | Maintains: Buy | $83 → $48 | $6.26 | +666.77% | 6 | Aug 18, 2025 | |
| CMPS COMPASS Pathways | Maintains: Buy | $15 | $6.89 | +117.71% | 4 | Aug 1, 2025 | |
| CRVO CervoMed | Maintains: Buy | $21 → $27 | $8.42 | +220.67% | 6 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $265 → $220 | $174.82 | +25.84% | 21 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $3.99 | +200.75% | 5 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $112 → $80 | $1.73 | +4,524.28% | 7 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $28 | $12.75 | +119.61% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $27.83 | +18.58% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $10.50 | +1,328.57% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $31.54 | - | 2 | Jan 31, 2017 |
Cybin
Nov 20, 2025
Maintains: Buy
Price Target: $70 → $45
Current: $7.85
Upside: +473.25%
Mind Medicine (MindMed)
Nov 7, 2025
Maintains: Buy
Price Target: $16 → $25
Current: $14.02
Upside: +78.32%
Zevra Therapeutics
Nov 6, 2025
Maintains: Buy
Price Target: $25 → $24
Current: $8.53
Upside: +181.36%
Stoke Therapeutics
Nov 5, 2025
Maintains: Buy
Price Target: $24 → $28
Current: $31.86
Upside: -12.12%
Neurocrine Biosciences
Oct 29, 2025
Maintains: Buy
Price Target: $160 → $164
Current: $147.28
Upside: +11.35%
Atai Beckley
Oct 22, 2025
Maintains: Buy
Price Target: $11 → $14
Current: $4.33
Upside: +223.33%
Annovis Bio
Sep 30, 2025
Maintains: Buy
Price Target: $17
Current: $3.58
Upside: +374.86%
Clene
Aug 18, 2025
Maintains: Buy
Price Target: $83 → $48
Current: $6.26
Upside: +666.77%
COMPASS Pathways
Aug 1, 2025
Maintains: Buy
Price Target: $15
Current: $6.89
Upside: +117.71%
CervoMed
Jul 29, 2025
Maintains: Buy
Price Target: $21 → $27
Current: $8.42
Upside: +220.67%
May 2, 2025
Maintains: Buy
Price Target: $265 → $220
Current: $174.82
Upside: +25.84%
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $3.99
Upside: +200.75%
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $1.73
Upside: +4,524.28%
Nov 18, 2024
Maintains: Buy
Price Target: $31 → $28
Current: $12.75
Upside: +119.61%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $27.83
Upside: +18.58%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $10.50
Upside: +1,328.57%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $31.54
Upside: -